


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A therapeutic or preventive agent for ischemic nerve injury ~~due to nerve cell death by ischemic disorder~~ containing a compound ~~having a semaphorin inhibitory activity which is obtained by culturing Penicillium sp. SPF-3059 strain and~~ represented by formula-[1] [22]:



~~wherein a dashed line represents a single bond or double bond, and R¹ represents a hydrogen atom, a carboxy group or an alkoxy carbonyl group, and R² represents a hydrogen atom, a hydroxyl group or an acyloxy group, and R⁷ and R⁸ independently represent a hydrogen atom or an organic group; a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.~~


2.-7. (canceled).

8. (previously presented): The therapeutic or preventive agent according to claim 1, wherein the ischemic nerve injury is retinal neuropathy.

9. (original): The therapeutic or preventive agent according to claim 8 wherein the retinal neuropathy is glaucoma, diabetic retinopathy, macular degeneration or retinopathy of prematurity.


10. (previously presented): The therapeutic or preventive agent according to claim 1, wherein the ischemic nerve injury is cerebral embolism, transient cerebral ischemia, subclavian steal syndrome, Wallenberg syndrome (lateral medullary syndrome), cerebral thrombosis, lacunar infarct, reversible ischemic neurological deficit, cerebral infarction, moyamoya disease (occlusion of the circle of Willis), hypoxic encephalopathy, sinus venosus thrombosis or postoperative spinal cord ischemia.

11. (new): A method for treating or preventing ischemic nerve injury due to nerve cell death by ischemic disorder, comprising administering an effective amount of a compound represented by formula [22]:



or a pharmaceutically acceptable salt thereof to a subject in need thereof.

12. (new): A method for suppressing nerve cell death by ischemic disorder, comprising administering an effective amount of a compound represented by formula [22]:



or a pharmaceutically acceptable salt thereof to a subject in need thereof.